Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/2477| Drug repurposing against MERS CoV and SARS-COV-2 PLpro in silico | |
| Elfiky Abdo. Ibrahim Noha. Elshemey Wael. | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| 10.21203/rs.3.rs-19600/v1 | |
| Aim: The Middle East Respiratory Syndrome coronavirus (MERS-CoV) and COVID-19 cause severe acute, deadly, pneumonia. Papain-like protease (PLpro), is HCoV cysteine protease encoded within the Non-Structural protein 3. Materials and Methods: Molecular docking is performed to test the binding performance of six protease inhibitors against MERS CoV and SARS-CoV-2 PLpro. Results: The compound, GRL-0667, shows the highest binding affinity to MERS CoV PLpro, while Grazoprevir shows the highest binding affinity against HCV NS3. Moreover, the interaction pattern in the case of HCV NS3 is the same as in the case of coronaviruses. Conclusion: The present study shows the ability of some anti-SARS CoV and anti-HCV NS3 drugs to inhibit MERS CoV PLpro, interestingly, including the newly emerged SARS-COV-2 PLpro. | |
| assets.researchsquare.com | |
| 2020 | |
| Artículo | |
| https://assets.researchsquare.com/files/rs-19600/v1/manuscript.pdf | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 1101822.pdf | 2.28 MB | Adobe PDF | Visualizar/Abrir |